Middlebrook Pharmaceuticals, Inc. - Current report filing (8-K)
04 3월 2008 - 8:59PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
March 4, 2008
Date of Report
(Date of earliest event reported)
MIDDLEBROOK PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50414 52-2208264
-------- --------- ----------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
|
20425 Seneca Meadows Parkway, Germantown, Maryland 20876
(Address of Principal Executive Offices) (ZIP Code)
Registrant's telephone number, including area code: (301) 944-6600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On March 4, 2008, MiddleBrook Pharmaceuticals, Inc. issued a press release
announcing its financial results for the three months and twelve months ended
December 31, 2007. A copy of the release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto shall not
be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act
of 1934, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description
------- -----------
99.1 Press Release issued March 4, 2008
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MIDDLEBROOK PHARMACEUTICALS, INC.
Date: March 4, 2008 By: /s/ Robert C. Low
----------------------------------
Robert C. Low
Vice President, Finance and
Chief Financial Officer
|
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Middlebrook Pharmaceuticals (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Middlebrook Pharmaceuticals, Inc. News Articles